(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 101.31% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Autolus Therapeutics's revenue in 2026 is $51,128,000.On average, 13 Wall Street analysts forecast AUTL's revenue for 2026 to be $38,380,523,274, with the lowest AUTL revenue forecast at $28,621,048,976, and the highest AUTL revenue forecast at $50,106,796,455. On average, 12 Wall Street analysts forecast AUTL's revenue for 2027 to be $67,243,762,641, with the lowest AUTL revenue forecast at $48,454,046,649, and the highest AUTL revenue forecast at $89,144,693,646.
In 2028, AUTL is forecast to generate $116,208,804,399 in revenue, with the lowest revenue forecast at $77,104,371,387 and the highest revenue forecast at $156,646,615,274.